165 related articles for article (PubMed ID: 16283867)
1. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers.
Margolis DJ; Bartus C; Hoffstad O; Malay S; Berlin JA
Wound Repair Regen; 2005; 13(6):531-6. PubMed ID: 16283867
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
Lantis JC; Boone D; Gendics C; Todd G
Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers.
Margolis DJ; Kantor J; Santanna J; Strom BL; Berlin JA
Diabetes Care; 2001 Mar; 24(3):483-8. PubMed ID: 11289472
[TBL] [Abstract][Full Text] [Related]
4. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
Fernández-Montequín JI; Infante-Cristiá E; Valenzuela-Silva C; Franco-Pérez N; Savigne-Gutierrez W; Artaza-Sanz H; Morejón-Vega L; González-Benavides C; Eliseo-Musenden O; García-Iglesias E; Berlanga-Acosta J; Silva-Rodríguez R; Betancourt BY; López-Saura PA;
Int Wound J; 2007 Dec; 4(4):333-43. PubMed ID: 17953679
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis.
Zhao XH; Gu HF; Xu ZR; Zhang Q; Lv XY; Zheng XJ; Yang YM
Metabolism; 2014 Oct; 63(10):1304-13. PubMed ID: 25060693
[TBL] [Abstract][Full Text] [Related]
6. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group.
Steed DL; Donohoe D; Webster MW; Lindsley L
J Am Coll Surg; 1996 Jul; 183(1):61-4. PubMed ID: 8673309
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group.
Steed DL
J Vasc Surg; 1995 Jan; 21(1):71-8; discussion 79-81. PubMed ID: 7823364
[TBL] [Abstract][Full Text] [Related]
8. Growth factors for treating diabetic foot ulcers.
Martí-Carvajal AJ; Gluud C; Nicola S; Simancas-Racines D; Reveiz L; Oliva P; Cedeño-Taborda J
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD008548. PubMed ID: 26509249
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
10. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
Bhansali A; Venkatesh S; Dutta P; Dhillon MS; Das S; Agrawal A
Diabetes Res Clin Pract; 2009 Jan; 83(1):e13-6. PubMed ID: 19081156
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: a retrospective series.
Harrison-Balestra C; Eaglstein WH; Falabela AF; Kirsner RS
Dermatol Surg; 2002 Aug; 28(8):755-9; discussion 759-60. PubMed ID: 12174074
[TBL] [Abstract][Full Text] [Related]
12. Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials.
Sridharan K; Sivaramakrishnan G
Br J Clin Pharmacol; 2018 Mar; 84(3):434-444. PubMed ID: 29148070
[TBL] [Abstract][Full Text] [Related]
13. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus.
Liu Z; Dumville JC; Hinchliffe RJ; Cullum N; Game F; Stubbs N; Sweeting M; Peinemann F
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010318. PubMed ID: 30328611
[TBL] [Abstract][Full Text] [Related]
14. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
Ma C; Hernandez MA; Kirkpatrick VE; Liang LJ; Nouvong AL; Gordon II
Wounds; 2015 Apr; 27(4):83-91. PubMed ID: 25855851
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
Steed DL
Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial.
Nevins M; Giannobile WV; McGuire MK; Kao RT; Mellonig JT; Hinrichs JE; McAllister BS; Murphy KS; McClain PK; Nevins ML; Paquette DW; Han TJ; Reddy MS; Lavin PT; Genco RJ; Lynch SE
J Periodontol; 2005 Dec; 76(12):2205-15. PubMed ID: 16332231
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
Gilligan AM; Waycaster CR; Motley TA
Wound Repair Regen; 2015; 23(3):353-60. PubMed ID: 25810233
[TBL] [Abstract][Full Text] [Related]
18. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers.
Kallianinen LK; Hirshberg J; Marchant B; Rees RS
Plast Reconstr Surg; 2000 Nov; 106(6):1243-8. PubMed ID: 11083552
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
20. The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers.
Kahraman M; Misir A; Kizkapan TB; Ozcamdalli M; Uzun E; Mutlu M
J Foot Ankle Surg; 2019 Mar; 58(2):282-287. PubMed ID: 30612874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
